Invivyd Inc. (IVVD) | Stock Price, Analysis, News, Fundaments & Technical Information

stock

Invivyd Inc.

NASDAQ | IVVD

0.55

USD

-0.0291 (-5.03%)

AT CLOSE (AS OF Apr 3, 2025)

$69M

MARKET CAP

P/E Ratio

-1.43

EPS

$3.9

52 Week High

$0.36

52 Week Low

LIFE SCIENCES

Sector

IVVD Chart

Area

Trade Smarter

Take control of your trading journey with a set of smart tools for serious trades

Backtests

Strategy Backtester designed to automate your backtesting and revolutionize the way you trade

Learn More About Backtests

Scanner

Leverage the power of AI to detect valuable opportunities and gain the most out of the markets.

Learn More About Scanner

Signals

Automate your trading workflow with AI-powered trading signals to execute trades automatically.

Learn More About Signals

Journal

Record your trades and performance to improve your trading with AfterPullback’s Trading Journal

Learn More About Journal

IVVD Technicals

Tags:

IVVD Earnings

Yearly Income Statement (As of Dec 31, 2023)

Field	Value (USD)
Gross Profit	-$49M
Total Revenue	-
Cost Of Revenue	$49M
Costof Goods And Services Sold	$2M
Operating Income	-$213M
Selling General And Administrative	$49M
Research And Development	$159M
Operating Expenses	$213M
Investment Income Net	-
Net Interest Income	-
Interest Income	-
Interest Expense	-
Non Interest Income	-
Other Non Operating Income	-
Depreciation	$480K
Depreciation And Amortization	$2M
Income Before Tax	-$199M
Income Tax Expense	$0
Interest And Debt Expense	-
Net Income From Continuing Operations	-$199M
Comprehensive Income Net Of Tax	-$198M
Ebit	-$213M
Ebitda	-$197M
Net Income	-$199M

Revenue & Profitability

Earnings Performance

IVVD Financials

Highlights

Balance Sheet

Cash Flow

Income Statement

Yearly

Quarterly

yearly Balance Sheet (As of Dec 31, 2023)

Field	Value (USD)
Total Assets	$229M
Total Current Assets	$225M
Cash And Cash Equivalents At Carrying Value	$201M
Cash And Short Term Investments	$201M
Inventory	$0
Current Net Receivables	$933K
Total Non Current Assets	$4.3M
Property Plant Equipment	$1.9M
Accumulated Depreciation Amortization Ppe	-
Intangible Assets	-
Intangible Assets Excluding Goodwill	-
Goodwill	-
Investments	$0
Long Term Investments	-
Short Term Investments	-
Other Current Assets	$22M
Other Non Current Assets	$175K
Total Liabilities	$52M
Total Current Liabilities	$50M
Current Accounts Payable	$8M
Deferred Revenue	$0
Current Debt	-
Short Term Debt	$1.4M
Total Non Current Liabilities	$1.4M
Capital Lease Obligations	$2.2M
Long Term Debt	$1B
Current Long Term Debt	-
Long Term Debt Noncurrent	-
Short Long Term Debt Total	$1B
Other Current Liabilities	$35K
Other Non Current Liabilities	$700K
Total Shareholder Equity	$177M
Treasury Stock	-
Retained Earnings	-$732M
Common Stock	$11K
Common Stock Shares Outstanding	$110M

yearly Cash Flow (As of Dec 31, 2023)

Field	Value (USD)
Operating Cashflow	-$173M
Payments For Operating Activities	-
Proceeds From Operating Activities	-
Change In Operating Liabilities	$25M
Change In Operating Assets	$19M
Depreciation Depletion And Amortization	-$642K
Capital Expenditures	$615K
Change In Receivables	-
Change In Inventory	-
Profit Loss	-$199M
Cashflow From Investment	$281M
Cashflow From Financing	$1M
Proceeds From Repayments Of Short Term Debt	-
Payments For Repurchase Of Common Stock	$1K
Payments For Repurchase Of Equity	$1K
Payments For Repurchase Of Preferred Stock	-
Dividend Payout	-
Dividend Payout Common Stock	-
Dividend Payout Preferred Stock	-
Proceeds From Issuance Of Common Stock	$240K
Proceeds From Issuance Of Long Term Debt And Capital Securities Net	-
Proceeds From Issuance Of Preferred Stock	-
Proceeds From Repurchase Of Equity	$1.2M
Proceeds From Sale Of Treasury Stock	-
Change In Cash And Cash Equivalents	-
Change In Exchange Rate	-
Net Income	-$199M

yearly Income Statement (As of Dec 31, 2023)

Field	Value (USD)
Gross Profit	-$49M
Total Revenue	-
Cost Of Revenue	$49M
Costof Goods And Services Sold	$2M
Operating Income	-$213M
Selling General And Administrative	$49M
Research And Development	$159M
Operating Expenses	$213M
Investment Income Net	-
Net Interest Income	-
Interest Income	-
Interest Expense	-
Non Interest Income	-
Other Non Operating Income	-
Depreciation	$480K
Depreciation And Amortization	$2M
Income Before Tax	-$199M
Income Tax Expense	$0
Interest And Debt Expense	-
Net Income From Continuing Operations	-$199M
Comprehensive Income Net Of Tax	-$198M
Ebit	-$213M
Ebitda	-$197M
Net Income	-$199M

IVVD Profile

Invivyd Inc. Profile

Sector: LIFE SCIENCES

Industry: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)

Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases in the United States. The company is headquartered in Waltham, Massachusetts.

Symbol	Price	Change %	Market Cap	Volume
DMN	$0.02	13.04%	-	706,860,781
NVDA	$101.80	-7.81%	$2.68T	334,149,797
INTC	$22.43	2.05%	$95.85B	240,924,655
F	$9.55	-5.96%	$39.53B	213,326,329
LCID	$2.32	-3.33%	$7.67B	210,875,217

Symbol	Price	Change %	Market Cap	Volume
JNJ	$160.56	3.35%	$399.65B	9,908,361
PG	$172.57	1.81%	$399.61B	6,993,394
NVO	$67.12	-1.65%	$308.32B	8,797,694
AZN	$74.03	2.50%	$225.70B	6,150,517
MRK	$86.38	-0.25%	$220.07B	12,113,104

Symbol	Price	Change %	Market Cap	Volume
VCIG	$6.06	1,818.33%	$26.40M	302,396
MKTW	$9.19	1,684.81%	$19.91M	117,875
ICCT	$4.38	111.59%	$9.78M	168,784,937
PTIX	$0.42	84.14%	$4.04M	177,332,811
MRM	$0.65	74.84%	$2.91M	51,693,935

Symbol	Price	Change %	Market Cap	Volume
ALDX	$1.42	-73.33%	$326.91M	21,865,554
RFAC	$2.70	-68.60%	$8.44M	605,339
PKBO	$0.02	-67.86%	$531.87K	66,140
TCBP	$0.50	-67.53%	$360.37K	1,955,586
OMQS	$0.04	-66.36%	$1.50M	950,669

Quick Links

IVVD $0.55 (-5.03%) Quote details